Guilford mother fights for mental health law
GUILFORD, Conn. (WTNH) — A Guilford mother is trying to get the law changed about mental health after her son went to prison for a stabbing. Dennis House talks with Denise Paley and State Sen. Christine Cohen about new legislative action to provide more access to mental health care on This Week In Connecticut.
Watch above.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Proposed bill would allow Pennsylvania students to take mental health days
PENNSYLVANIA (WTAJ) — A representative announced plans to model new legislation after a current Utah law that allows students to take mental health days. Representative Napoleon Nelson (D-Montgomery County) called mental health a 'significant issue' among students and youth. Adding that in a 2023 report, 98,000 students have depression and over half had not received care for their mental health. 'Additionally, high school students with depression are more than two times more likely to drop out than their peers, and suicide is the second leading cause of death among adolescents,' Nelson wrote. 'Fanta's Law' aims to require Pennsylvania police firearms training courses The proposed legislation would be modeled after a current law in Utah. The bill would allow students to take excused absences to recover from mental health issues, while not creating additional personal or sick days. An additional part of the legislation would require a staff member to talk to a student who has taken two or more mental health days. In a memo to lawmakers, the additional part of the legislation would make it so that students can be connected to mental health support. 'Student mental health is just as important as physical health, and normalizing support for students with mental health issues has increased in the last several years. Teen mental health has been recognized as a crisis, and it is important for the Commonwealth to take charge in protecting the well-being of its citizens,' Nelson wrote. Nelson argues that these are the benefits of the proposed legislation: Normalizes mental health support and encourages students to take care of their mental health Provides schools with additional insight Would allow schools to connect students with essential supports rather than simply punishing them The full memo to lawmakers can be read here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 50,200 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on June 2, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted with a 10-year term and an exercise price equal to $15.40, the closing price per share of Spyre's common stock as reported by Nasdaq on June 2, 2025. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee's start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at View original content to download multimedia: SOURCE Spyre Therapeutics, Inc.
Yahoo
2 hours ago
- Yahoo
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the 'Company' or '89bio') (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 61,100 shares of the Company's common stock to three new employees (the 'Inducement Grants') on June 3, 2025 (the 'Grant Date'). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the 'Plan'). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates. About 89bio 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit or follow the company on LinkedIn. Investor Contact:Annie Chang89bio, PJ KelleherLifeSci Advisors, LLC+1-617-430-7579pkelleher@ Media Contact:Sheryl SeapyReal Chemistrysseapy@
